ArticleJAMA network open2023

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.

Thierry André et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.